##### 



Exhibit
99.1


|Acumen BioFin

Rodman & Renshaw

9th Annual

Healthcare Conference



November 5, 2007
|--------------------------------------------------------------------------------------



---



##### 



|Forward-Looking Statements

This presentation contains "forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements are subject to certain risks, trends and uncertainties that
could cause actual results to differ materially from those projected. Among these risks, trends and
uncertainties are decisions by the U.S. Federal and Drug Administration  (FDA) regarding whether and
when to approve THELIN(tm) ; timing and outcome of regulatory action on competing products in the EU;
the availability of financing and revenues sufficient to fund research and development of THELIN,
TBC3711 and our other product candidates, commercial business operations and to repay our
outstanding indebtedness; our estimate of the sufficiency of our existing capital resources; market
acceptance of THELIN in the EU, Canada and Australia and the actual rate of acceptance; our ability to
raise additional capital to fund cash requirements for future commercial and research and development
operations; the accuracy of our estimates concerning market sizes and patient populations for PAH,
diastolic heart failure, resistant hypertension and other therapeutic categories in which we are
developing our products; the timing and cost of our clinical trials and the success of our drug
development activities; the scope of our own patents and our ability to protect our patents and other
intellectual property for THELIN, TBC3711 and our other products under development; potential delays
in the timelines for initiating clinical trials, enrolling patients and obtaining results of clinical trials with
respect to THELIN, TBC3711 and our other products under development; our ability to attract and retain
qualified personnel; reduced estimates concerning the PAH patient population and PAH diagnosis rates
in markets where THELIN(tm) is approved; our inability to predict revenues from THELIN in the EU, Canada
and Australia and expense levels in 2007 and beyond; the ability of our subsidiary to repay the notes
secured by royalties on Argatroban sales by GSK; our ability to quickly and successfully commercialize
THELIN in the EU, Canada and Australia; and the impact of reimbursement policies and government
regulation of prices on THELIN(tm) revenues in the EU, Canada, and Australia as well as the speed with
which pricing and reimbursement approvals and product launches for THELIN may be achieved in Italy
and other countries of the EU, Canada and Australia. In particular, careful consideration should be given
to cautionary statements made in the various reports Encysive Pharmaceuticals Inc. has filed with the
Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the
fiscal year ended December 31, 2006, and in its reports on Forms 10-Q and 8-K. The Company
undertakes no duty to update or revise these forward-looking statements.
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Investment Highlights

Two Marketed Products

THELIN(r) (sitaxentan sodium) developed by Encysive and is
approved in the EU, Canada and Australia

THELIN is indicated for the treatment of pulmonary arterial
hypertension (PAH)

Argatroban was developed by Encysive and is marketed by
GlaxoSmithKline in the U.S. and Canada

Argatroban is indicated for the treatment of heparin-induced
thrombocytopenia

Royalty stream has been monetized

Robust Pipeline

Four phase II studies underway

THELIN and TBC3711 being evaluated in large market
cardiovascular disease opportunities
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Lead Product/Program - THELIN in PAH

Pulmonary Arterial Hypertension (PAH)

Rare, life-threatening condition causing high blood
pressure in the lungs due to narrowing and stiffening of
pulmonary arteries

Symptoms include shortness of breath, fatigue, dizzy
spells, fainting, chest pain, and swelling of ankles and legs

PAH may develop without a known cause (primary or
idiopathic disease)

PAH is more commonly related to other conditions, such
as connective tissue disease (e.g., systemic lupus or
scleroderma), congenital heart disease or HIV
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|THELIN is Approved in Markets Generating
$450 Million Today

THELIN is approved for treatment of PAH in Europe,
Canada and Australia

Today, we estimate these markets are growing at greater
than 30% with projected 2007 ETRA category sales of
>$450 million*

THELIN is launched in UK, Germany, Ireland,
Netherlands, Spain and France

Commercial launch in Italy - 4Q 2007

Canada's Common Drug Review - Process expected to
continue into next year

*Source: Encysive Pharmaceuticals Inc. Internal Market Estimates
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|European Operations Established

Encysive headquartered outside London, UK

Approximately 35 sales reps when fully
launched

Sales to date largely from UK and Germany

Launched in Spain in September and in France
in October

2008: Big five EU countries will be selling
Thelin
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|European Commercial Team

Thierry Plouvier, MD - VP, Europe

Organon, Chiesi, Lilly

Carl Sterritt, EU Operations

United Therapeutics, Europe

Phina Deichmann, EU Marketing

Chiron

Andreas Off - Germany

GSK, BMS Oncology

Francesco Arcudi - Italy

Dompe

Eva Begaud - France

TKT

Stephen Tague - UK

Neu-Tec, Gilead
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Encysive EU:

Headquarter-Based Medical Team

Christian Schweiger, MD, PhD

Medical Director Europe, Sr Director Encysive

Physician by training, PhD in Clinical Pharmacology at the University of
Hamburg

Ed Parsley, D.O.

Executive Director, Global Medical Affairs

Oklahoma State University of Osteopathic Medicine and Surgery; Board
Certified Internal Medicine, Pulmonary Medicine, Critical Care Medicine
and Sleep Medicine

Neil Davie, PhD

Director of Scientific Affairs

Imperial College School of Medicine, PhD in Cell and Molecular Biology

Tommy A Brock, PhD

Medical Science Liaison Consultant, Europe

Professor of Internal Medicine, University of Texas Medical School at
Houston, experience and extensive in-depth knowledge of vascular biology
and cardiovascular therapies

Heather Giles, PhD

VP, Technical Operations (Europe) and Strategic Planning

 PhD in Pharmacology from University College, London; GlaxoSmithKline
R&D and GlaxoWellcome R&D
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Encysive EU:

Country-Based Medical Team

Bernhard Kaumanns, MD

Medical Director Germany-Austria-Swiss

Trauma & Orthopedic Surgery, University of Aachen

Andrew Saich, BSc.(Hons) MRCP

Medical Director UK and Ireland

Royal College of Physicians, London, MRCP in General Medicine;
Charing Cross and Westminster Medical School, London, MBBS in
Emergency Medicine

Enrica Bucchioni, MD

Medical Director Italy

Medical Degree: University of Milan; Post-graduate specialty and
PhD in Respiratory Diseases: University of Milan and Imperial
College School of Medicine, London

Pilar Vallejo, MD, PhD

Medical Advisor Spain (Praxis)

Universidad Autonoma Madrid. Speciality in Clinical Microbiology
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|THELIN:  Competitive Profile

Once-daily oral tablet requiring no titration

Highly selective, with a high affinity for ETa

Only approved selective ETRA for PAH in the EU

Rate of liver enzyme elevations similar to placebo

Approved for primary PAH and PAH associated with
CTD

No clinically meaningful interaction with sildenafil

Only ETRA with comparator data

Easily managed interaction with warfarin
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|U.S. Regulatory Status

FDA says THELIN is "Approvable"

Agency recommends an additional Phase III trial for
marketing clearance

Encysive is now moving forward with study

STRIDE-5

Working with FDA to finalize a study protocol

Details of the study to be announced once protocol
discussions are concluded with FDA
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|U.S. PAH Market Will Remain Attractive

US ETRA market projected to exceed $1 billion in 2010*

Disease awareness will continue to expand diagnosis

ETRAs projected to remain a therapeutic mainstay

Encysive believes THELIN can capture a meaningful
share of ETRA market in the US


*Source: Encysive Pharmaceuticals Inc. Internal Market Estimates
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|PIPELINE

Leveraging the Therapeutic
Opportunity of ETRAs

Blocking Endothelin has potential in a wide range of
cardiovascular diseases
|---------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|THELIN in Diastolic Heart Failure (DHF)

Phase 2 trial fully enrolled

Approximately 150 DHF patients from 40 centers

Randomized, placebo controlled study

Primary endpoint: Change in exercise capacity

Data expected mid 2008

Positive results sets stage for initiation of pivotal studies
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Diastolic Heart Failure (DHF)

DHF characterized by the signs and symptoms of
chronic heart failure (historically known as CHF with
normal ejection rate)

Few studies focused only on DHF

Large Market Opportunity

Estimated 4.4 million patients in North America and
Europe*

Few treatment options available

*Source: Encysive Pharmaceuticals Inc. Internal Market Estimates
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Next Generation ETRA:  TBC3711

TBC3711 is Encysive's next generation, highly selective
ETRA

100,000 times selective for endothelin A receptor

More potent than THELIN

High oral bio-availability
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Resistant Hypertension (rHTN)

Defined as persistent blood pressure above 140/90 despite
treatment with three anti-hypertensive therapies, including
a diuretic

Easily identifiable patient population

By definition, area of high unmet medical need

Large Market Opportunity

Estimated 4.5 million existing patients in North America and
Europe*


*Source: Encysive Pharmaceuticals Inc. Internal Market Estimates
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Resistant Hypertension Study

Randomized, placebo controlled dose-ranging study

Approximately 150 patients

Primary endpoint: sitting and standing BPs taken pre-dose
and 2 hours post-dose during clinic visits

Enrollment ongoing

Positive results sets stage for initiation of pivotal studies
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Pipeline Chart

PROPRIETARY PRODUCTS

THELIN(tm) Oral

THELIN(tm) Oral- US

CCR9

PC2 Oral*

PC3 Intravenous

PAH

Undisclosed

ILD

THELIN(tm) Oral

Undisclosed

Post-surgery PH

TBC3711 Oral

THELIN(tm) Intravenous

TBC3711 Intravenous

IBD

Undisclosed

Undisclosed

Resistant HTN

Undisclosed

PARTNERED PRODUCTS

Argatroban

Bimosiamose

TBC4746

HIT, PCI

Asthma, Psoriasis

MS, Asthma

Pre-Clin    I         II             III            NDA             Market        Indication

-------------------   Phase   ------------------

THELIN(tm) Oral

DHF

THELIN(r)  Oral- EU, CA. AU

PAH

PAH

* In microdose testing
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Financial Highlights

   Cash, cash equivalents, accrued interest and restricted cash at 9/30/07   Cash, cash equivalents, accrued interest and restricted cash at 9/30/07   $54.2M

3Q 2007 Financial Snapshot:
3Q 2007 Financial Snapshot:
3Q 2007 Financial Snapshot:
   Revenues
Sales
Royalty Income
R&D Exp.
Sales & Marketing
G&A
Net loss   8.8M
$3.6M
$4.8M*
$7.4M
$6.8M
$5.6M
$22.5M   8.8M
$3.6M
$4.8M*
$7.4M
$6.8M
$5.6M
$22.5M

* Argatroban royalty income is used to pay the outstanding Argatroban notes, the royalty income is not available to fund operational requirements
* Argatroban royalty income is used to pay the outstanding Argatroban notes, the royalty income is not available to fund operational requirements
* Argatroban royalty income is used to pay the outstanding Argatroban notes, the royalty income is not available to fund operational requirements
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Upcoming Milestones

Commercial milestones

Reimbursement and launch of THELIN in Italy -  4Q '07

Clinical milestones

Report results from Phase 2 THELIN trial for Diastolic
Heart Failure  - mid 2008

CCR9 program to enter human testing for Inflammatory
Bowel Disease - 2008
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Key Personnel

George W. Cole, President and CEO

Joined Encysive in 2005 as COO, promoted to CEO in June 2007

Former President of Altana Pharma U.S, a subsidiary of Germany- based Altana Pharma AG

Richard Dixon, Ph.D., Senior VP, Research; CSO

Co-founded Encysive in 1989

Former Director and Head of Molecular Biology at Merck Sharp & Dohme Research Laboratories, a
division of Merck & Co

Thierry A. Plouvier, M.D., Vice President, European Operations

Joined Encysive in March 2006 to oversee operations in the European Union

Former President and Chief Executive Officer Previously at Organon SA

Jeffrey Keyser, VP, Regulatory Affairs

Joined Encysive in April 2004

Previously served as Vice President, Development and Regulatory Affairs of Adams Laboratories

Paul S. Manierre, Esq., VP and General Counsel

Joined Encysive in October 2005

Previously worked at Eisai Inc., a research-based pharmaceutical company where he served as
Associate General Counsel

Richard A. Goeggel, VP, Finance

Joined Encysive in 2001, appointed the Corporate Treasurer in 2006, promoted to VP  November 2007

Holds an A.B. in Economics, M.B.A. in Accounting and Finance and is C.P.A
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Forward-Looking Statements

This presentation contains "forward-looking statements" within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements are subject to certain risks, trends and uncertainties that
could cause actual results to differ materially from those projected. Among these risks, trends and
uncertainties are decisions by the U.S. Federal and Drug Administration  (FDA) regarding whether and
when to approve THELIN(tm) ; timing and outcome of regulatory action on competing products in the EU;
the availability of financing and revenues sufficient to fund research and development of THELIN,
TBC3711 and our other product candidates, commercial business operations and to repay our
outstanding indebtedness; our estimate of the sufficiency of our existing capital resources; market
acceptance of THELIN in the EU, Canada and Australia and the actual rate of acceptance; our ability to
raise additional capital to fund cash requirements for future commercial and research and development
operations; the accuracy of our estimates concerning market sizes and patient populations for PAH,
diastolic heart failure, resistant hypertension and other therapeutic categories in which we are
developing our products; the timing and cost of our clinical trials and the success of our drug
development activities; the scope of our own patents and our ability to protect our patents and other
intellectual property for THELIN, TBC3711 and our other products under development; potential delays
in the timelines for initiating clinical trials, enrolling patients and obtaining results of clinical trials with
respect to THELIN, TBC3711 and our other products under development; our ability to attract and retain
qualified personnel; reduced estimates concerning the PAH patient population and PAH diagnosis rates
in markets where THELIN(tm) is approved; our inability to predict revenues from THELIN in the EU, Canada
and Australia and expense levels in 2007 and beyond; the ability of our subsidiary to repay the notes
secured by royalties on Argatroban sales by GSK; our ability to quickly and successfully commercialize
THELIN in the EU, Canada and Australia; and the impact of reimbursement policies and government
regulation of prices on THELIN(tm) revenues in the EU, Canada, and Australia as well as the speed with
which pricing and reimbursement approvals and product launches for THELIN may be achieved in Italy
and other countries of the EU, Canada and Australia. In particular, careful consideration should be given
to cautionary statements made in the various reports Encysive Pharmaceuticals Inc. has filed with the
Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the
fiscal year ended December 31, 2006, and in its reports on Forms 10-Q and 8-K. The Company
undertakes no duty to update or revise these forward-looking statements.
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---



##### 



|Acumen BioFin

Rodman & Renshaw

9th Annual

Healthcare Conference



November 5, 2007
|--------------------------------------------------------------------------------------